Tetraphase Pharmaceuticals (TTPH) is set to take eravacycline (which is already being evaluated as an IV treatment for complicated intra-abdominal infections) into another Phase 3 trial.
The planned study is an IV/oral trial in patients with complicated urinary tract infections. (PR)
Needham's Alan Carr is out reiterating a Buy rating on the shares, noting that "commercially available oral agents for Gram negative infections have become less reliable due to resistance concerns and all other drugs in clinical development for Gram-negative infections are administered only by IV administration."
Price target hiked to $15 from $12.